Immunotherapy News and Research

Latest Immunotherapy News and Research

Cancer vaccine shows improved response rate in patients

Cancer vaccine shows improved response rate in patients

OncoSec Medical to present results of ElectroImmunotherapy clinical trial in melanoma at ASCO 2011

OncoSec Medical to present results of ElectroImmunotherapy clinical trial in melanoma at ASCO 2011

Adaptimmune announces opening of Phase I/II clinical trial in multiple myeloma

Adaptimmune announces opening of Phase I/II clinical trial in multiple myeloma

Pro-Pharmaceuticals announces name change to Galectin Therapeutics

Pro-Pharmaceuticals announces name change to Galectin Therapeutics

NWBT accelerates addition of clinical sites for new enrollment into ongoing GBM brain cancer trial

NWBT accelerates addition of clinical sites for new enrollment into ongoing GBM brain cancer trial

ImmunoCellular to present new ICT-107 Phase I trial data in glioblastoma multiforme at ASCO 2011

ImmunoCellular to present new ICT-107 Phase I trial data in glioblastoma multiforme at ASCO 2011

Scientists develop quick, low-cost microchip for immune monitoring and clinical applications

Scientists develop quick, low-cost microchip for immune monitoring and clinical applications

Jennerex presents positive preliminary data from JX-594 Phase 2 trial for advanced liver cancer

Jennerex presents positive preliminary data from JX-594 Phase 2 trial for advanced liver cancer

CEL-SCI initiates global Multikine Phase III trial for head and neck cancer in Russia

CEL-SCI initiates global Multikine Phase III trial for head and neck cancer in Russia

Advantagene reaches SPA agreement with FDA for ProstAtak Phase 3 trial to prevent prostate cancer recurrence

Advantagene reaches SPA agreement with FDA for ProstAtak Phase 3 trial to prevent prostate cancer recurrence

RXi to present updated NeuVax Phase II trial data in breast cancer at ASCO 2011

RXi to present updated NeuVax Phase II trial data in breast cancer at ASCO 2011

CITN selects Cytheris' CYT107 for initial clinical trials at network institutions

CITN selects Cytheris' CYT107 for initial clinical trials at network institutions

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Canada

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Canada

Preliminary topline results from Teva, CureTech's CT-011 Phase II trial in Diffuse Large B Cell Lymphoma

Preliminary topline results from Teva, CureTech's CT-011 Phase II trial in Diffuse Large B Cell Lymphoma

New biomarker can predict breast cancer recurrence

New biomarker can predict breast cancer recurrence

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Poland

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Poland

Simple tips for avoiding allergies and asthma during summer

Simple tips for avoiding allergies and asthma during summer

ImmunID, Centre Léon Bérard and Cytheris commence CYT107-XELODA Phase IIa trial in metastatic breast cancer

ImmunID, Centre Léon Bérard and Cytheris commence CYT107-XELODA Phase IIa trial in metastatic breast cancer

Inovio first quarter total revenue increases to $3.1 million for 2011

Inovio first quarter total revenue increases to $3.1 million for 2011

UCLA researchers amp up power of killer CD8 T-cells to fight melanoma

UCLA researchers amp up power of killer CD8 T-cells to fight melanoma

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.